Introduction: Anti-IL-2 receptor has been proven to be effective in reducing the rate of acute rejection in kidney transplantation. The aim of the present study was to analyze the efficacy of basiliximab used for induction treatment compared with no induction in live related renal transplantation.
Materials and Methods: It was a prospective study done in Kidney Foundation Hospital & Research Institute, Dhaka, Bangladesh over a period of two years. Total number of patient were 49 live related renal transplant recipients. In group A were 24 & group B 25. The group A received basiliximab 20 mg intravenously on postoperative days 0 and 4. The group B received no induction agents. Both groups received tacrolimus, MMF/azathioprine, and corticosteroids for maintenance immunosuppression.
Result: Total number of patient were 49. The mean ages of the recipients in group A and group B were 32.6±10.2 and 34.5±9.1 years respectively. Glomerulonephritis (84.6%) was the leading cause of ESRD. Parents (46.2%) were the main kidney donor. Graft rejection at 6th and 12th month in group A (n=24) were 4 (16.67%) vs. 6 (25.0%); p =.123 and in group B (n=25) were 5 (20%) vs. 6 (24%); p=.923 respectively. In both groups level of serum creatinine in mmol/L 151.3 ± 81.3 vs. 149.2 ±55.3, p=.860 at month 3; 150 ± 42.4 vs. 181 ±109, p=0.779 at month 6; 173.8 ± 119.7 vs. 175 ±131.4 p=0.879 at month 9; 182 ±104 vs. 191 ±126.4, p=.864 at month 12. During the study period in both groups developed CMV infection 4 (16.7%) vs. 5 (20%), p = 0.469; Tuberculosis 7 (29.2%) vs. 4.2%, p = 0.531& graft loss 1 (4.17%) vs. 2 (8%), p = 0.632. However, no significant difference was observed between the groups in terms of these complications (p > 0.05 in each case).
Conclusions: Basiliximab induction therapy did not provide clear clinical efficacy benefit or prove to be effective compared with no induction in live related renal transplantation.